<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158257</url>
  </required_header>
  <id_info>
    <org_study_id>XuanwuH202110</org_study_id>
    <nct_id>NCT05158257</nct_id>
  </id_info>
  <brief_title>Clinical Of Plain Balloon Dilatation Combined Study Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity</brief_title>
  <official_title>Clinical Of Plain Balloon Dilatation Combined Study Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective randomized controlled study to evaluate the difference of&#xD;
      safety，effectiveness between endovascular debulking combined drug-coated balloon and balloon&#xD;
      dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized controlled study to evaluate the difference of safety，effectiveness&#xD;
      between endovascular debulking combined drug-coated balloon and balloon dilatation combined&#xD;
      stent angioplasty in treatment of femoral-popliteal artery lesions. Patients with&#xD;
      femoral-popliteal artery lesions in our department were randomly assigned to the endovascular&#xD;
      debulking combined drug-coated balloon group and balloon dilatation combined with stent&#xD;
      angioplasty group. Compare the ischemic improvement rate (limb salvage rate, postoperative&#xD;
      patency rate) and the complications rate of two different treatments. At the same time, the&#xD;
      peri-operative related factors that may affect the end point events, such as preoperative&#xD;
      baseline data, lesion characteristics, imaging features, stent fracture, and end point&#xD;
      observation indexes were analyzed by regression analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Primary Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>systolic velocity ratio &gt;2.4 as measured by Duplex ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>1 day</time_frame>
    <description>Technical success was defined as residual stenosis less than 30% by final</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from clinically-driven TLR</measure>
    <time_frame>12 months</time_frame>
    <description>it is defined as the freedom from clinically-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month Limb Salvage Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Limb Salvage is defined as the freedom from secondary major amputation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Intervention: balloon and Stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>plain balloon and Stents group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention: debulking and drug coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>debulking and drug coated balloon group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon and Stent</intervention_name>
    <description>balloon dilatation combined stent angioplasty</description>
    <arm_group_label>Intervention: balloon and Stents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endovascular debulking and DCB</intervention_name>
    <description>endovascular debulking combined drug-coated balloon</description>
    <arm_group_label>Intervention: debulking and drug coated balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients were included if they were de novo stenosis&gt;70% or occlusion of the&#xD;
        femoropopliteal at least 18 years of age and referred for claudication (Rutherford-Becker&#xD;
        class II-III) or critical limb ischemia (Rutherford-Becker class IV-V). They were excluded&#xD;
        if they had one or more of the following: 1. Acute or subacute lower limb ischemia; 2.&#xD;
        Severe calcification lesions; 3. Total occlusions lesions more significant than 20 cm or&#xD;
        total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated&#xD;
        ipsilateral iliac artery stenosis&gt;70%, or the distal runoff artery &lt;1 root; 5. Previously&#xD;
        lower extremity intervention or surgical graft artery bypass; 6. Severe renal&#xD;
        insufficiency, creatinine level greater than 2.5 mg/dL; 7. The patient's platelet count is&#xD;
        less than 100,000/uL, antiplatelet or anticoagulant contraindications to required&#xD;
        medications; 8. Patients with immune system diseases or malignant tumours; 9. ongoing&#xD;
        active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11.&#xD;
        Unwillingness to return for future follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yang Li, M.D.</last_name>
    <phone>18810432268</phone>
    <email>liyang0603@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong quan Gu, M.D.</last_name>
    <phone>15901598209</phone>
    <email>15901598209@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gu Yong Quan</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian ming Guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Yong quan Gu, M.D.</last_name>
      <phone>15901598209</phone>
      <email>15901598209@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>debulking</keyword>
  <keyword>femoral artery</keyword>
  <keyword>drug-coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

